Benign prostatic hyperplasia (BPH), also known as benign prostatic
hypertrophy, is nonmalignant enlargement of the prostate gland. The
prostate gland surrounds the urethra, which excretes urine from the
bladder outside the body. Enlargement of the prostate gland leads to
blockage of the urethra, thus causing problems during urination. It
involves stromal and glandular epithelial hyperplasia, which occurs
in the periurethral transition zone surrounding the urethra. The
symptoms of benign prostatic hyperplasia includes urinary hesitancy,
straining in initiating urination, dribbling, decreased force of
stream, feeling of incomplete bladder emptying, frequent urination,
dysuria and nocturia. Benign prostatic hyperplasiais is distinguished
by progressive development of lower urinary tract symptoms (LUTS) due
to prolonged obstruction of urine. The prevalence of LUTS due to
benign prostatic hyperplasia increases with increasing age. In around
80% of men, moderate to severe symptoms are observed between the age
of 60 to 80 years. The treatment options for benign prostatic
hyperplasia are therapeutic and surgical procedures.
Report Overview @
https://www.transparencymarketresearch.com/benign-prostatic-hyperplasia-treatment-devices-market.html
Benign prostatic hyperplasia occurs in almost all men. It is not
cancer, and about 50% of men aged over 75 years have some symptoms of
benign prostatic hyperplasia. It is usually caused by abnormal
hormonal balance, and changes in cell growth. Increasing aging
population worldwide, increasing prevalence and incidence of benign
prostatic hyperplasia is a major driving force for the benign
prostatic hyperplasia treatment device market. Increase in awareness
of prostate cancer and urological disorders, new and innovative
device development, and high rate of adoption of minimally invasive
devices for treatment is further driving the growth of the market.
High unmet needs associated with benign prostatic hyperplasia have
encouraged key players to invest in research and development
activities to develop novel devices at low cost for treatment of
benign prostatic hyperplasia which has further contributed to the
market growth globally. Medication treatment of benign prostatic
hyperplasia usually leads to invasive procedures and leads to side
effects due to which key players are taking initiatives to invent new
devices which offer less invasive treatment for enlarged prostate
treatment.
The global benign prostatic hyperplasia market can be segmented by
procedure type and end users. By procedure type, the market is
segmented into laser based procedure and other energy based
procedure. Laser based procedures can be segmented further into
holmium lasers, green light laser, and thulium laser based devices.
Other energy based procedures are transurethral microwave
thermotherapy, transurethral needle ablation, high-intensity focused
ultrasound (HIFU), water-induced thermotherapy, prostatic artery
embolization, and prostatic implants. Prostatic implants are further
segmented into stents and prostatic urethral lift devices.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26861
By end users, the market is segmented into hospitals, ambulatory
surgical centers, specialty clinics, and others. Hospitals account
for the dominant market share of the benign prostatic hyperplasia
market due to high rate of hospitalization of patients suffering from
urological disorder in hospitals and early adoption of new devices in
hospitals.
Geographically, the global benign prostatic hyperplasia market is
distributed over North America, Europe, Asia Pacific, Latin America,
and Middle East & Africa. North America is projected to hold a
significant share in the market due to the rising prevalence of
benign prostatic hyperplasia, rise in geriatric population, and
increase in healthcare expenditure. Alliances between public and
private sectors for the development of low-cost medical devices, and
favorable reimbursement policies are also likely to propel the market
in North America. The high incidence of urological disorders, rising
incidence of benign prostatic hyperplasia in developing countries,
and investment from key players in emerging economies with huge
patient population are anticipated to drive the market in the Asia
Pacific region.
Major players operating in the benign prostatic hyperplasia market
include Endo International, Karl Storz, Lumenis, Olympus, Urologix,
NeoTract Inc. Boston Scientific Inc., Urotech Inc., and others.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=26861<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment